HNN3.0
Register
Register
Register

Project cooperationUpdated on 8 January 2026

Transfection-free AAV production

Head of Technology Development at ReiThera srl

Rome, Italy

About

ReiThera offers its proprietary AdAAV technology, a transfection-free AAV manufacturing platform designed to address key scalability barriers limiting the transition of gene therapies from clinical success to commercial success.

The AdAAV platform is compatible with suspension cell culture and is suited for standardized manufacturing workflows, supporting cost containment, and long-term supply reliability.

As an SME technology partner, ReiThera can contribute to collaborative projects through:

  • Transfection-free AAV manufacturing process development and optimization

  • Scale-up and GMP-oriented process design

  • Development of analytical methods and quality control strategies

  • Translational support bridging preclinical development, clinical manufacturing, and early commercial considerations

ReiThera seeks to participate in Horizon Europe consortia by providing its AdAAV platform and industrial expertise, without acting as project coordinator, supporting projects aiming to transform innovative gene therapies into viable and accessible medicinal products.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Type

  • Partner seeks Consortium/Coordinator

Organisation

ReiThera srl

Company (SME)

Rome, Italy

Similar opportunities

  • Project cooperation

    process development & GMP manufacturing of viral vectors

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

    Stefania Capone

    Grant Projects Director at ReiThera srl

    Rome, Italy

  • Project cooperation

    Adenoviral vaccine platform

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy

  • Project cooperation

    Modified Vaccinia Ankara (MVA) platform for strong T-cell immune responses

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy